Difference between revisions of "Mogamulizumab (Poteligeo)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replacement - "Category:Drug index" to "Category:Drugs")
m
Line 1: Line 1:
−
=Mechanism of action=
+
==Mechanism of action==
 
From the [http://www.cancer.gov/drugdictionary?CdrID=500479 NCI Drug Dictionary]: A humanized monoclonal antibody directed against C-C chemokine receptor 4 (CCR4) with potential anti-inflammatory and antineoplastic activities. Mogamulizumab selectively binds to and blocks the activity of CCR4, which may inhibit CCR4-mediated signal transduction pathways and, so, chemokine-mediated cellular migration and proliferation of T cells, and chemokine-mediated angiogenesis. In addition, this agent may induce antibody-dependent cell-mediated cytotoxicity (ADCC) against CCR4-positive T cells. CCR4, a G-coupled-protein receptor for C-C chemokines such MIP-1, RANTES, TARC and MCP-1, is expressed on the surfaces of some types of T cells, endothelial cells, and some types of neurons.
 
From the [http://www.cancer.gov/drugdictionary?CdrID=500479 NCI Drug Dictionary]: A humanized monoclonal antibody directed against C-C chemokine receptor 4 (CCR4) with potential anti-inflammatory and antineoplastic activities. Mogamulizumab selectively binds to and blocks the activity of CCR4, which may inhibit CCR4-mediated signal transduction pathways and, so, chemokine-mediated cellular migration and proliferation of T cells, and chemokine-mediated angiogenesis. In addition, this agent may induce antibody-dependent cell-mediated cytotoxicity (ADCC) against CCR4-positive T cells. CCR4, a G-coupled-protein receptor for C-C chemokines such MIP-1, RANTES, TARC and MCP-1, is expressed on the surfaces of some types of T cells, endothelial cells, and some types of neurons.
  
−
=Preliminary results=
+
==Diseases for which it is used==
 +
*[[Adult T-cell leukemia-lymphoma]]
 +
*[[Cutaneous T-cell lymphoma]]
 +
*[[Peripheral T-cell lymphoma]]
  
−
==[[Adult T-cell leukemia-lymphoma]]==
+
==History of changes in FDA indication==
−
# Ishida T, Jo T, Takemoto S, Suzushima H, Uozumi K, Yamamoto K, Uike N, Saburi Y, Nosaka K, Utsunomiya A, Tobinai K, Fujiwara H, Ishitsuka K, Yoshida S, Taira N, Moriuchi Y, Imada K, Miyamoto T, Akinaga S, Tomonaga M, Ueda R. Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: a randomized phase II study. Br J Haematol. 2015 Jun;169(5):672-82. Epub 2015 Mar 2. [https://onlinelibrary.wiley.com/doi/10.1111/bjh.13338/full link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/25733162 PubMed]
+
*8/8/2018: Initial FDA approval "for adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy."
  
−
==[[Cutaneous T-cell lymphoma]]==
+
==Also known as==
−
# Ogura M, Ishida T, Hatake K, Taniwaki M, Ando K, Tobinai K, Fujimoto K, Yamamoto K, Miyamoto T, Uike N, Tanimoto M, Tsukasaki K, Ishizawa K, Suzumiya J, Inagaki H, Tamura K, Akinaga S, Tomonaga M, Ueda R. Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma. J Clin Oncol. 2014 Apr 10;32(11):1157-63. Epub 2014 Mar 10. [http://jco.ascopubs.org/content/32/11/1157.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/24616310 PubMed]
+
*'''Code name:''' KW-0761
−
# Duvic M, Pinter-Brown LC, Foss FM, Sokol L, Jorgensen JL, Challagundla P, Dwyer KM, Zhang X, Kurman MR, Ballerini R, Liu L, Kim YH. Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma. Blood. 2015 Mar 19;125(12):1883-9. Epub 2015 Jan 20. [http://www.bloodjournal.org/content/125/12/1883.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/25605368 PubMed]
+
*'''Generic name:''' mogamulizumab-kpkc
−
 
+
*'''Brand name:''' Poteligeo
−
==[[Peripheral T-cell lymphoma]]==
 
−
# Ogura M, Ishida T, Hatake K, Taniwaki M, Ando K, Tobinai K, Fujimoto K, Yamamoto K, Miyamoto T, Uike N, Tanimoto M, Tsukasaki K, Ishizawa K, Suzumiya J, Inagaki H, Tamura K, Akinaga S, Tomonaga M, Ueda R. Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma. J Clin Oncol. 2014 Apr 10;32(11):1157-63. Epub 2014 Mar 10. [http://jco.ascopubs.org/content/32/11/1157.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/24616310 PubMed]
 
  
 
[[Category:Drugs]]
 
[[Category:Drugs]]
 +
[[Category:Intravenous medications]]
  
−
[[Category:Immunotherapy]]
 
 
[[Category:Antibody medications]]
 
[[Category:Antibody medications]]
 
[[Category:Anti-CCR4 antibodies]]
 
[[Category:Anti-CCR4 antibodies]]
 
[[Category:Anti-CD194 antibodies]]
 
[[Category:Anti-CD194 antibodies]]
  
 +
[[Category:Adult T-cell leukemia-lymphoma medications]]
 
[[Category:Cutaneous T-cell lymphoma medications]]
 
[[Category:Cutaneous T-cell lymphoma medications]]
 
[[Category:Peripheral T-cell lymphoma medications]]
 
[[Category:Peripheral T-cell lymphoma medications]]
  
−
[[Category:Investigational]]
+
[[Category:FDA approved in 2018]]

Revision as of 17:54, 10 August 2018

Mechanism of action

From the NCI Drug Dictionary: A humanized monoclonal antibody directed against C-C chemokine receptor 4 (CCR4) with potential anti-inflammatory and antineoplastic activities. Mogamulizumab selectively binds to and blocks the activity of CCR4, which may inhibit CCR4-mediated signal transduction pathways and, so, chemokine-mediated cellular migration and proliferation of T cells, and chemokine-mediated angiogenesis. In addition, this agent may induce antibody-dependent cell-mediated cytotoxicity (ADCC) against CCR4-positive T cells. CCR4, a G-coupled-protein receptor for C-C chemokines such MIP-1, RANTES, TARC and MCP-1, is expressed on the surfaces of some types of T cells, endothelial cells, and some types of neurons.

Diseases for which it is used

History of changes in FDA indication

  • 8/8/2018: Initial FDA approval "for adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy."

Also known as

  • Code name: KW-0761
  • Generic name: mogamulizumab-kpkc
  • Brand name: Poteligeo
Retrieved from "https://hemonc.org/w/index.php?title=Mogamulizumab_(Poteligeo)&oldid=29838"